Zoetis Inc (NYSE:ZTS)
| 184.62 Delayed Data As of Dec 08 |  +2.79 / +1.53%Today’s Change | 140.76 Today|||52-Week Range 194.99 | +25.98% Year-to-Date |
Latest ZTS News | Press Releases
| GRFS vs. ZTS: Which Stock Is the Better Value Option? Dec 07 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 181.83 |
| Today’s open | 181.83 |
| Day’s range | 181.48 - 184.84 |
| Volume | 1,474,667 |
| Average volume (3 months) | 1,786,733 |
| Market cap | $82.2B |
Data as of 3:59pm ET, 12/08/2023
Growth & Valuation
| Earnings growth (last year) | +4.99% |
| Earnings growth (this year) | +10.70% |
| Earnings growth (next 5 years) | +10.91% |
| Revenue growth (last year) | +3.91% |
| P/E ratio | 37.6 |
| Price/Sales | 8.53 |
| Price/Book | 20.41 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VRTXVertex Pharmaceutica... | -3.92 | -1.11% |
| REGNRegeneron Pharmaceut... | -9.16 | -1.08% |
| ---- | ||
| GSKGlaxoSmithKline | -0.05 | -0.14% |
Data as of 4:00pm ET, 12/08/2023
Financials
| Next reporting date | February 15, 2024 |
| EPS forecast (this quarter) | $1.40 |
| Annual revenue (last year) | $8.1B |
| Annual profit (last year) | $2.1B |
| Net profit margin | 26.16% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Parsippany, New Jersey |
Forecasts
